# Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9)

> **NCT05633992** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 450 (actual)

## Conditions studied

- Pneumococcal Disease

## Interventions

- **BIOLOGICAL:** V116
- **BIOLOGICAL:** PPSV23

## Key facts

- **NCT ID:** NCT05633992
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-10
- **Primary completion:** 2023-05-24
- **Final completion:** 2023-05-24
- **Target enrollment:** 450 (ACTUAL)
- **Last updated:** 2024-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05633992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05633992, "Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05633992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*